IAVI Announces First-in-Human Clinical Trial of Native-like HIV Envelope Vaccine Candidate
Phase I Trial to Evaluate Safety and Immunogenicity of Engineered Envelope Protein NEW YORK–(BUSINESS WIRE)–The International AIDS Vaccine Initiative (IAVI)…
Pharmaceuticals, Biotechnology and Life Sciences
Phase I Trial to Evaluate Safety and Immunogenicity of Engineered Envelope Protein NEW YORK–(BUSINESS WIRE)–The International AIDS Vaccine Initiative (IAVI)…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/RSV?src=hash” target=”_blank”gt;#RSVlt;/agt;–Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced…
Potential to target GPRC5D in multiple myeloma patients relapsed after BCMA-targeted therapy EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical stage…
First Oral Norovirus GII.4 Tablet Vaccine Used in Clinical Trial SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., a clinical-stage biotechnology company…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/AXAcandidates?src=hash” target=”_blank”gt;#AXAcandidateslt;/agt;–Axcella Health, a biotechnology company pioneering the research and development of novel multifactorial interventions to address…
— More Than 35 Abstracts Across NASH, PSC and Viral Hepatitis Reflect Ongoing Commitment to Advancing Liver Disease Research and…
SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNVD), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective…
New preclinical data to be presented on Core inhibitor EDP-514 targeting HBV FXR agonist EDP-305 targeting NASH ASK-1 inhibitors EP-026856…
Novartis on Wednesday said that it got approval from the FDA for Mayzent for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults.
First prophylactic vaccine to demonstrate proof of concept for CMV control independent of human leukocyte antigen (HLA) status in stem…